Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Dermatologic 2Breast 2Thoracic 1Genitourinary 1

Conditions

Melanoma 20Glioblastoma 12Neoplasms 10Breast Neoplasms 10Pancreatic Neoplasms 9Glioma 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Fallopian Tube Neoplasms 4Carcinoma 4Astrocytoma 4Oligodendroglioma 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 125Nivolumab 84pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 42Leucovorin 40tremelimumab 37Radiofrequency Ablation 37camrelizumab 36Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28Hepatectomy 26Gemcitabine 26Cyclophosphamide 26cabozantinib 25Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × poly ICLC × Clear all
NCT04116320 2025-07-14

AM-003

University of Virginia

Phase 1 Terminated
5 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT05281926 2022-03-16

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

National Taiwan University Hospital

Phase 1 Unknown
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00553683 2014-01-14

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Rutgers, The State University of New Jersey

Phase 1/2 Unknown
50 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡